Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the non-small-cell lung cancer (NSCLC) drug market will exceed $4.1 billion in 2012. According to the new Pharmacor study entitled Non-Small-Cell Lung Cancer, the NSCLC drug market will be impacted by generic erosion when three major chemotherapy drugs go off patent. Aventis's Taxotere patent expires in 2007 in Europe and in 2010 in the United States; Bristol-Myers Squibb's Paraplatin patent expires in 2004 in the United States; and between 2004 and 2010, Eli Lilly's Gemzar patent expires in all European countries and the United States.

"Although chemotherapy drugs will experience generic erosion within the next ten years, the use of chemotherapy will increase, primarily in earlier stages of NSCLC," said Mohamed Muhsin, analyst at Decision Resources. "Chemotherapy is not currently part of standard treatment of early-stage disease. However, as oncologists recognize the improvements in quality of life that chemotherapy can provide, an increasing proportion of these patients will be referred for chemotherapy by primary care physicians and pulmonologists. The increased use of chemotherapy and the emergence of targeted therapies will be the major NSCLC market drivers over the next ten years."

About Non-Small-Cell Lung Cancer

Lung cancer accounts for 25% of all cancer deaths in women and more than 30% of cancer deaths in men. It is one of the most common cancers in industrialized nations and an increasing problem in developing countries. NSCLC, a heterogeneous disease that encompasses several types, accounts for 80-85% of lung cancers. Because only a minority of patients live for more than one year after diagnosis and the five-year survival rate is less than 15%, NSCLC has generated a huge unmet need for more-effective therapies that can prevent disease recurrence and have fewer toxic side effects than current therapies.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Non-Small-Cell Lung Cancer is an Onkos study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., 1-781-296-2563,
emarshall@dresources.com

Long-Term Outlook Bleak For Mid-Sized, Research-Based Pharmaceutical Companies

View Now